Connective tissue growth factor activates pluripotency genes and mesenchymal-epithelial transition in head and neck cancer cells

Cancer Research

Volumn 73, Issue 13, 2013, Pages 4147-4157

  Chang, Cheng Chi ^a   Hsu, Wen Hao ^a   Wang, Chen Chien ^a   Chou, Chun Hung ^f   Kuo, Mark Yen Ping ^a   Lin, Been Ren ^b   Chen, Szu Ta ^b   Tai, Shyh Kuan ^c   Kuo, Min Liang ^e   Yang, Muh Hwa ^d,f,g  

^a School of Dentistry   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c Department of Otolaryngology ^*  (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN C JUN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UVOMORULIN; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER STEM CELL; CONNECTIVE TISSUE GROWTH FACTOR GENE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NANOG GENE; NONHUMAN; ONCOGENE C JUN; POU5F1 GENE; PRIORITY JOURNAL; SOX2 GENE; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; BINDING SITES; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE-FREE SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HEK293 CELLS; HOMEODOMAIN PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-JUN; SOXB1 TRANSCRIPTION FACTORS; SPHEROIDS, CELLULAR; TRANSCRIPTIONAL ACTIVATION; TRANSCRIPTOME;

EID: 84880061588     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4085     Document Type: Article

References (40)

1. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119: 1420-8.
2. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139: 871-90.
3. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133: 704-15.
4. Morel AP, Liévre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008;3: e2888.
5. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012;12: 133-43.
6. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009;11: 1487-95.
7. Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH, et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 2010;12: 982-92.
8. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126: 663-76.
9. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318: 1917-20.
10. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008;451: 141-6.
11. Li R, Liang J, Ni S, Zhou T, Qing X, Li H, et al. A mesenchymal- toepithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 2010;7: 51-63.
12. Samavarchi-Tehrani P, Golipour A, David L, Sung HK, Beyer TA, Datti A, et al. Functional genomics reveals a BMP-driven mesenchymal-toepithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010;7: 64-77.
13. Redmer T, Diecke S, Grigoryan T, Quiroga-Negreira A, Birchmeier W, Besser D. E-cadherin is crucial for embryonic stem cell pluripotency and can replace OCT4 during somatic cell reprogramming. EMBORep 2011;12: 720-6.
14. Ocaña OH, Nieto MA. Epithelial plasticity, stemness and pluripotency. Cell Res 2010;20: 1086-8.
15. Luft FC. CCN2, the connective tissue growth factor. J Mol Med 2008;86: 1-3.
16. Chu CY, Chang CC, Prakash E, Kuo ML. Connective tissue growth factor (CTGF) and cancer progression. J Biomed Sci 2008;15: 675-85.
17. Pan LH, Beppu T, Kurose A, Yamauchi K, Sugawara A, Suzuki M, et al. Neoplastic cells and proliferating endothelial cells express connective tissue growth factor (CTGF) in glioblastoma. Neurol Res 2002;24: 677-83.
18. Chen PS, Wang MY, Wu SN, Su JL, Hong CC, Chuang SE, et al. CTGF enhances the motility of breast cancer cells via an integrin-avb3- ERK1/2-dependent S100A4-upregulated pathway. J Cell Sci 2007; 120: 2053-65.
19. Chang CC, Shih JY, Jeng YM, Su JL, Lin BZ, Chen ST, et al.Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst 2004;96: 364-75.
20. Lin BR, Chang CC, Che TF, Chen ST, Chen RJ, Yang CY, et al. Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer. Gastroenterology 2005;128: 9-23.
21. Garavello W, Ciardo A, Spreafico R, Gaini RM. Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006;132: 762-6.
22. Yang MH, Chang CH, Lin BR, Chen ST, Lin SK, Kuo MY, et al. Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling. Oncogene 2012;31: 2401-11.
23. Wong YK, Chang KW, Chen CF, Chang CS. Characterization of two new cell lines derived from oral cavity human squamous cell carcinomas - OC1 and OC2. J Oral Maxillofac Surg 1990;48: 385-90.
24. Kok SH, Hong CY, Lin SK, Lee JJ, Chiang CP, Kuo MY. Establishment and characterization of a tumorigenic cell line from areca quid and tobacco smoke-associated buccal carcinoma. Oral Oncol 2007;43: 639-47.
25. http://www.cbil.upenn.edu/cgi-bin/tess/tess.
26. http://alggen.lsi.upc.es/recerca/frame-recerca.html.
27. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell. Properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007;104: 973-8.
28. Glinsky GV. Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol 2008;26: 2846-53.
29. Chambers I, Tomlinson SR. The transcriptional foundation of pluripotency. Development 2009;136: 2311-22.
30. Shaulian E. AP-1-the jun proteins: oncogenes or tumor suppressors in disguise? Cell Signal 2010;22: 894-9.
31. Mork J, Glattre E. Squamous cell carcinomas of the head and neck in Norway, 1953-92: an epidemiologic study of a low-risk population. Cancer Causes Control 1998;9: 37-48.
32. Chiang CT, Hwang YH, Su CC, Tsai KY, Lian IeB, Yuan TH, et al. Elucidating the underlying causes of oral cancer through spatial clustering in high-risk areas of Taiwan with a distinct gender ratio of incidence. Geospat Health 2010;4: 230-242.
33. Nakerakanti SS, Bujor AM, Trojanowska M. CCN2 is required for the TGF-b induced activation of Smad1-Erk1/2 signaling network. PLoS ONE 2011;6: e21911.
34. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. Head and neck. In: American Joint Committee on Cancer (AJCC) cancer staging manual. 6th ed., New York, NY: Springer; 2002. p. 17-68.
35. Celiá-Terrassa T, Meca-Cortés O, Mateo F, de Paz AM, Rubio N, Arnal-Estapé A, et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest 2012;122: 1849-68.
36. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celiá-Terrassa T, et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 2011;17: 1101-8.
37. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S, et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS ONE 2010;5: e12445.
38. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 2010;70: 10433-44.
39. Han X, Fang X, Lou X, Hua D, Ding W, Foltz G, et al. Silencing SOX2 induced mesenchymal-epithelial transition and its expression predicts liver and lymph node metastasis of CRC patients. PLoS ONE 2012;7: e41335.
40. Hu J, Qin K, Zhang Y, Gong J, Li N, Lv D, et al. Downregulation of transcription factor Oct4 induces an epithelial-to-mesenchymal transition via enhancement of Ca2+ influx in breast cancer cells. Biochem Biophys Res Commun 2011;411: 786-91.